Parenteral Manual

Magnesium sulfate

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Magnesium sulfate
Classification: 
Electrolyte, Anticonvulsant
Original Date: 
August 2005
Revised Date: 
August 2024
Indications: 
  • Magnesium replacement
  • Treatment of seizures and encephalopathy associated with acute nephritis
  • Treatment of hypertension
  • Treatment and prevention of Torsade de Pointes
  • Adjunctive treatment for bronchodilation in moderate to severe asthma (unlabeled use)
  • Treatment of chronic pain/migraine
  • Hypomagnesemia during a code transfusion (massive hemorrhage)
Reconstitution and Stability: 
  • Prepared SYRINGE of magnesium sulfate 40 mg/mL 

  • Prepared IV BAGS for infusion:  2 to 4 mmol Magnesium sulfate/L ( equals 500 to 1000 mg Magnesium/L) 

Compatibility: 

- Solutions Compatible: dextrose solutions,0.9% NaCl, dextrose-saline combinations, ringer's solution, ringer's lactate

- Additives/Above Cassette Compatible: KCl

- Y-site Compatible: cefazolin, cefotaxime, dobutamine, heparin, KCl, morphine, TPN (amino acids/dextrose), vancomycin

- Incompatible:  furosemide

Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

  • SC
NO
IM

NO

IV Intermittent
Critical care areas, SPOT TEAM, ED and

MDU for chronic pain

YES  SYRINGE PUMPrespiratory and cardiac monitoring
Usual dilution: 40 mg/mL of magnesium sulfate/mL

Infusion rate: do not exceed 150 mg magnesium sulfate/minute
Infusion time: 20 - 60 minutes

IV Intermittent Infusion - Pediatric Units

YES  SYRINGE PUMP -  respiratory and cardiac monitoring
Usual dilution: 40 mg/mL of magnesium sulfate

Infusion time: 1- 4 hours

IV Continuous Infusion

YES  - SYRINGE PUMP

Usual Dilution: 0.16 mmol/mL (magnesium sulfate 40 mg/mL)

Infusion time: Max rate of 0.25 mL/kg/hour

YES - LARGE VOLUME PUMP in Oncology

Usual Dilution:  2 to 4 mmol magnesium /L of IV solution

 

Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

PEDIATRIC:

-Management of seizures:

Use prepared SYRINGE of magnesium sulfate 40 mg/mL

Dose: 20 to 100 mg magnesium sulfate /kg/dose IV Q4-6H PRN

May use up to 200 mg magnesium sulfate/kg/dose

 

-Broncholidation, as adjunctive therapy

Use prepared SYRINGE of magnesium sulfate 40 mg/mL

Dose: 25 to 50 mg magnesium sulfate /kg/dose IV x 1 dose

Maximum single dose: 2000 mg magnesium sulfate

A few reports in literature describe administration of a second dose in 4 - 6 hours if clinically necessary
 

- Hypomagnesemia in PICU
Use prepared SYRINGE of magnesium sulfate 40 mg/mL

Dose: 25 to 50 mg/kg/dose IV Q4-6H x 3-4 doses

Higher doses up to 100 mg/kg/dose have been used

Maximum single dose: 2000 mg magnesium sulfate

 

- Prevention of torsade de pointes, for QTc > 500ms:
Use prepared SYRINGE of magnesium sulfate 40 mg/mL

Dose: 25 to 50 mg/kg/dose IV x 1 dose

Maximum single dose: 2000 mg magnesium sulfate

 

- Replacement for hypomagnesemia:

Dose: 10 mg/kg/hour IV (MAX 500 mg/hr) x 4 hours (then reassess)
 

-Prevention/Treatment of cisplatin-induced hypomagnesemia in Oncology:

Use IV solution prepared by Pharmacy (2 to 4 mmol Magnesium/L of IV solution)

-Hyperkalemia during a code transfusion (massive hemorrhage)

  • 25-50mg/kg over 20 minutes (max: 2 grams)
  • Followed by infusion of 15 mg/kg/hr target of serum Mg > 1.5 mmol/mL
    • If serum Mg >2.0 mmol/mL, reduce infusion by 50%

ADULT:
- Hypomagnesemia:       

  • 1000 mg magnesium sulfate IM/IV Q 6 hours x 4 doses
  • Maximum single dose: 2000 mg magnesium sulfate

- Management of seizures:  1000 mg magnesium sulfate IM/IV Q 6 hours PRN

- Bronchodilation: 2000 mg magnesium sulfate as a single dose

Potential hazards of parenteral administration: 

- Adverse effects are often related to the magnesium serum levels:

  • CNS depression
  • Hypotension
  • Muscle weakness
  • Flushing of skin, somnolence, sweating
  • Depressed deep tendon reflexes (patellar reflex) at magnesium serum concentrations > 10 mmol/L and absent at 20 mmol/L
  • Respiratory depression and complete heart block may occur at magnesium levels greater than 20 mmol/L
  • NOTE:  magnesium toxicity is exacerbated by hypocalcemia
Notes: 
  • Monitor urine output.  During infusion, monitor for cardiac dysrhythmias, hypotension, respiratory and CNS depression
  • Serum magnesium levels recommended if dosing is prolonged, continuous infusion is employed or in patients with renal failure
  • Hypomagnesemia may contribute to the development of digoxin toxicity.  However, supplementation with magnesium should be carried out slowly (over several days) because magnesium re-equilibrates slowly and because hypermagnesemia may cause arrhythmias and alter cardiac conduction, leading to heart block
  • Contraindicated in: heart block, serious renal impairment
  • Antidote for respiratory depression is calcium chloride or calcium gluconate
  • IV onset: immediate (as an anticonvulsant)
  • IV duration: 30 minutes (as an anticonvulsant)

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.